The estimated Net Worth of Kevin Forrest is at least $841 Thousand dollars as of 31 March 2017. Dr Forrest owns over 12,500 units of Cidara Therapeutics Inc stock worth over $840,753 and over the last 9 years he sold CDTX stock worth over $0.
Dr has made over 4 trades of the Cidara Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 12,500 units of CDTX stock worth $96,875 on 31 March 2017.
The largest trade he's ever made was buying 12,500 units of Cidara Therapeutics Inc stock on 31 March 2017 worth over $96,875. On average, Dr trades about 5,172 units every 82 days since 2015. As of 31 March 2017 he still owns at least 72,354 units of Cidara Therapeutics Inc stock.
You can see the complete history of Dr Forrest stock trades at the bottom of the page.
Dr. Kevin M. Forrest Ph.D. is the Founder and Chief Strategy Officer at Cidara Therapeutics Inc.
Dr D is 44, he's been the Founder and Chief Strategy Officer of Cidara Therapeutics Inc since . There are 18 older and no younger executives at Cidara Therapeutics Inc. The oldest executive at Cidara Therapeutics Inc is Dr. Kenneth F. Bartizal Ph.D., 70, who is the Chief Devel. Officer.
Kevin's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.
Over the last 15 years, insiders at Cidara Therapeutics Inc have traded over $256,071 worth of Cidara Therapeutics Inc stock and bought 1,216,676 units worth $9,796,257 . The most active insiders traders include Capital Management, L.P.Ra ..., Target N Vbb Biotech Ag Bio..., and Steve Elms. On average, Cidara Therapeutics Inc executives and independent directors trade stock every 52 days with the average trade being worth of $282,598. The most recent stock trade was executed by Jeffrey Stein on 7 June 2024, trading 8,000 units of CDTX stock currently worth $105,680.
cidara is a biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard of care therapies. our first product candidate is cd101 iv, a potential once-weekly intravenous therapy being developed for the treatment and prevention of systemic fungal infections. our second product candidate, cd101 topical, is a topical formulation of cd101, the first topical application of the enchinocandin class of anti-fungals, for the treatment of vulvovaginal candidiasis, or vvc. in addition, we have developed a proprietary immunotherapy technology platform, cloudbreak™, which we use to create compounds designed to direct a patient’s immune cells to attack and eliminate pathogens that cause infectious disease. we are developing our first cloudbreak development candidate, c001, for the treatment of invasive aspergillosis.
Cidara Therapeutics Inc executives and other stock owners filed with the SEC include: